3/13
02:27 am
biib
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]
Low
Report
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]
3/11
05:28 pm
biib
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? [Yahoo! Finance]
Low
Report
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? [Yahoo! Finance]
3/11
11:23 am
biib
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock [Yahoo! Finance]
Low
Report
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock [Yahoo! Finance]
3/11
08:03 am
biib
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy [Yahoo! Finance]
Low
Report
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy [Yahoo! Finance]
3/11
08:00 am
biib
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Low
Report
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
3/10
06:18 am
biib
Aduhelm (Biogen, Eisai) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Low
Report
Aduhelm (Biogen, Eisai) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
3/9
12:53 pm
biib
Navigating Postpartum Depression [Globe and Mail, The (Toronto, Canada)]
Low
Report
Navigating Postpartum Depression [Globe and Mail, The (Toronto, Canada)]
3/6
04:31 pm
biib
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]
Low
Report
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]
3/5
08:48 am
biib
What Makes Biogen (BIIB) an Attractive Long-Term Holding? [Yahoo! Finance]
Low
Report
What Makes Biogen (BIIB) an Attractive Long-Term Holding? [Yahoo! Finance]
3/5
08:08 am
biib
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences [Yahoo! Finance]
Low
Report
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences [Yahoo! Finance]
3/5
07:30 am
biib
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Low
Report
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
3/4
05:40 pm
biib
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome [Yahoo! Finance]
Low
Report
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome [Yahoo! Finance]
3/4
05:05 pm
biib
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Low
Report
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
2/21
06:31 am
biib
Biogen (NASDAQ:BIIB) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Biogen (NASDAQ:BIIB) was upgraded by analysts at Barclays PLC to a "hold" rating.
2/19
09:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at Barclays PLC.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at Barclays PLC.
2/13
10:11 am
biib
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here's Why [Yahoo! Finance]
Low
Report
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here's Why [Yahoo! Finance]
2/11
05:00 pm
biib
Biogen Announces Board Chair Transition
Low
Report
Biogen Announces Board Chair Transition
2/11
09:19 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $207.00 to $236.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $207.00 to $236.00. They now have an "outperform" rating on the stock.
2/9
03:02 pm
biib
Biogen (NASDAQ:BIIB) was given a new $231.00 price target on by analysts at Wolfe Research.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $231.00 price target on by analysts at Wolfe Research.
2/9
02:11 pm
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
2/9
11:43 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Citigroup Inc. from $185.00 to $215.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Citigroup Inc. from $185.00 to $215.00. They now have a "neutral" rating on the stock.
2/9
10:06 am
biib
Biogen (NASDAQ:BIIB) was given a new $230.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Biogen (NASDAQ:BIIB) was given a new $230.00 price target on by analysts at Canaccord Genuity Group Inc..
2/9
09:18 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Royal Bank Of Canada from $217.00 to $233.00. They now have an "outperform" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Royal Bank Of Canada from $217.00 to $233.00. They now have an "outperform" rating on the stock.
2/9
08:58 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Truist Financial Corporation from $190.00 to $193.00. They now have a "hold" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Truist Financial Corporation from $190.00 to $193.00. They now have a "hold" rating on the stock.
2/9
08:45 am
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at TD Cowen.
Medium
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at TD Cowen.